EPHA2 Antibody

The EPH receptor A2 (EphA2) is a member of the Eph receptor family, which is the largest subgroup of receptor tyrosine kinases (RTKs). Eph receptors and their ligands, ephrins, play crucial roles in various biological processes, including cell growth, migration, and tissue development. EphA2, in particular, has been extensively studied for its involvement in cancer progression and metastasis.

EphA2 is a transmembrane protein that consists of an extracellular domain, a single transmembrane segment, and an intracellular tyrosine kinase domain. The extracellular domain is responsible for binding to ephrin ligands, which are membrane-bound proteins. Upon ligand binding, EphA2 undergoes dimerization and autophosphorylation, leading to the activation of downstream signaling pathways.

EphA2 primarily interacts with ephrin-A family members, including ephrin-A1 to ephrin-A5. These interactions regulate various cellular processes such as cell adhesion, shape, and mobility. EphA2 is also involved in angiogenesis, the formation of new blood vessels, which is a critical process in tumor growth and metastasis.

EphA2 is overexpressed in various types of cancers, including breast, lung, prostate, and colorectal cancers. Its overexpression is often associated with poor prognosis and increased tumor aggressiveness. EphA2 promotes cancer cell proliferation, migration, and invasion by activating several signaling pathways, including the PI3K/AKT and MAPK pathways.

In addition to its role in cancer cell behavior, EphA2 also contributes to the tumor microenvironment by promoting angiogenesis and vasculogenic mimicry. Vasculogenic mimicry refers to the ability of aggressive cancer cells to form vessel-like structures, providing an alternative blood supply to the tumor.

Given its significant role in cancer progression, EphA2 has emerged as a potential therapeutic target. Several strategies have been developed to inhibit EphA2 signaling, including monoclonal antibodies, small molecule inhibitors, and ligand-based approaches. These therapies aim to block EphA2 activation, thereby inhibiting tumor growth and metastasis.

Mouse anti-human EphA2 antibodies are monoclonal antibodies developed to specifically recognize and bind to human EphA2. These antibodies are commonly used in research to study EphA2 expression and function in various experimental settings. They are also utilized in diagnostic applications to detect EphA2 levels in tissue samples.

One such antibody is the Mouse Anti-Human EphA2 Monoclonal Antibody (Clone 371805), which has been shown to detect EphA2 in direct ELISAs and Western blots without cross-reactivity with other Eph receptors . This antibody is used in various applications, including flow cytometry and immunocytochemistry, to study EphA2 expression in cancer cells .